Real-World Osteoporosis Treatment Gap and Costs in Spain: Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis

Overview

Journal Rheumatol Ther

Specialty Rehabilitation Medicine

Date 2025 Feb 11

PMID 39932674

Authors

Antoni Sicras-Mainar

Francesc Sorio-Vilela

Marta Sacrest-Soy

Sonia Gatell

Aram Sicras-Navarro

Renata Villoro-Valdes

Elena Rebollo-Gomez

Ignacio Hernandez

Affiliations

Soon will be listed here.

Abstract

Introduction: Postmenopausal osteoporosis (PMO) increases the risk of fragility fractures (FF), leading to disability, higher mortality, and elevated healthcare costs. Despite available treatments, osteoporosis (OP) remains undertreated, especially in women over 50 years at high risk for FF. Real-world data on OP care in Spain are limited. This study aims to assess the OP treatment gap, healthcare resource utilisation (HCRU), and costs among Spanish women following a first FF or PMO diagnosis.

Methods: This retrospective study used data from the BIG-PAC administrative database on women aged ≥ 50 years with a first FF (cohort 1) or newly diagnosed PMO (cohort 2) between 2014 and 2018. Patients were followed for 2 years after the index event. The primary outcome was the proportion of women not prescribed OP medication within 6 months after the index event (treatment gap). Secondary outcomes included fracture incidence, mortality, HCRU, and costs.

Results: The study included 22,142 women: 3190 in cohort 1 and 18,952 in cohort 2. The OP treatment gap was higher in cohort 1 vs cohort 2 (41.5% vs 23.6%). In cohort 1, 59.2% were diagnosed with PMO after the first FF, with 88% experiencing subsequent fracture(s). OP treatment persistence decreased over time in both cohorts. Fracture rates were lower in women prescribed OP treatment vs those who were not (8.35 vs 13.8 per 1000 patient-years) and in those who showed 24-month-persistence and 12-month adherence to treatment vs those who did not (8.98 and 7.66 vs 10.79 and 10.76). The 2-year mean cost per patient was higher in cohort 1 (€10,601) than in cohort 2 (€1659), with the highest costs incurred for hip (€15,833) and vertebral (€10,593) fractures.

Conclusion: This study highlights a significant treatment gap in Spanish women aged ≥ 50 with a first FF or newly diagnosed PMO. Costs are particularly high for those with a first FF, especially for hip or vertebral fractures. Improving treatment adherence could reduce fracture risk, healthcare costs, and resource utilisation.

References

Raisz L . Pathogenesis of postmenopausal osteoporosis. Rev Endocr Metab Disord. 2001; 2(1):5-12. DOI: 10.1023/a:1010074422268. View

Kanis J, Norton N, Harvey N, Jacobson T, Johansson H, Lorentzon M . SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021; 16(1):82. PMC: 8172408. DOI: 10.1007/s11657-020-00871-9. View

Bliuc D, Nguyen N, Milch V, Nguyen T, Eisman J, Center J . Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009; 301(5):513-21. DOI: 10.1001/jama.2009.50. View

Kanis J, Johansson H, McCloskey E, Liu E, Akesson K, Anderson F . Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. Osteoporos Int. 2023; 34(12):2027-2045. PMC: 7615305. DOI: 10.1007/s00198-023-06870-z. View

Colon-Emeric C, Kuchibhatla M, Pieper C, Hawkes W, Fredman L, Magaziner J . The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003; 14(11):879-83. DOI: 10.1007/s00198-003-1460-x. View

Teng G, Curtis J, Saag K . Mortality and osteoporotic fractures: is the link causal, and is it modifiable?. Clin Exp Rheumatol. 2008; 26(5 Suppl 51):S125-37. PMC: 4124750. View

Borgstrom F, Karlsson L, Ortsater G, Norton N, Halbout P, Cooper C . Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 2020; 15(1):59. PMC: 7166207. DOI: 10.1007/s11657-020-0706-y. View

Abrahamsen B, Skjodt M, Vestergaard P . Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention. Bone. 2018; 120:476-481. DOI: 10.1016/j.bone.2018.12.016. View

Lagari V, McAninch E, Baim S . Considerations regarding adherence of anti-osteoporosis therapy. Postgrad Med. 2014; 127(1):92-8. DOI: 10.1080/00325481.2015.993278. View

10.

Mugnier B, Daumas A, Couderc A, Mizzi B, Gonzalez T, Amrani A . Clinical effectiveness of osteoporosis treatment in older patients: A fracture liaison service-based prospective study. J Women Aging. 2018; 31(6):553-565. DOI: 10.1080/08952841.2018.1529473. View

11.

Sambrook P, Cranney A, Adachi J . Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. Curr Med Res Opin. 2010; 26(3):599-604. DOI: 10.1185/03007990903512321. View

12.

Mitchell P, Cooper C, Fujita M, Halbout P, Akesson K, Costa M . Quality Improvement Initiatives in Fragility Fracture Care and Prevention. Curr Osteoporos Rep. 2019; 17(6):510-520. DOI: 10.1007/s11914-019-00544-8. View

13.

Akesson K, McGuigan F . Closing the Osteoporosis Care Gap. Curr Osteoporos Rep. 2021; 19(1):58-65. PMC: 7935825. DOI: 10.1007/s11914-020-00644-w. View

14.

Kanis J, Cooper C, Rizzoli R, Reginster J . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2018; 30(1):3-44. PMC: 7026233. DOI: 10.1007/s00198-018-4704-5. View

15.

Sicras-Mainar A, Sicras-Navarro A, Palacios B, Varela L, Delgado J . Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Rev Esp Cardiol (Engl Ed). 2020; 75(1):31-38. DOI: 10.1016/j.rec.2020.09.033. View

16.

Steiner J, Prochazka A . The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50(1):105-16. DOI: 10.1016/s0895-4356(96)00268-5. View

17.

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J . Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations.... Arch Osteoporos. 2013; 8:136. PMC: 3880487. DOI: 10.1007/s11657-013-0136-1. View

18.

Martinez-Laguna D, Carbonell C, Bastida J, Gonzalez M, Mico-Perez R, Vargas F . Prevalence and treatment of fragility fractures in Spanish primary care: PREFRAOS study. Arch Osteoporos. 2022; 17(1):93. PMC: 9283348. DOI: 10.1007/s11657-022-01124-7. View

19.

McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E . The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int. 2020; 32(2):251-259. PMC: 7838133. DOI: 10.1007/s00198-020-05557-z. View

20.

Fatoye F, Smith P, Gebrye T, Yeowell G . Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019; 9(4):e027049. PMC: 6500256. DOI: 10.1136/bmjopen-2018-027049. View